Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire Intuniv trials meet objectives

Shire Intuniv trials meet objectives

20th May 2009

Shire’s investigation of Intuniv (guanfacine) extended release has met its primary objectives.

The selective alpha-2A-agonist is intended to aid the symptoms of attention deficit hyperactivity disorder (ADHD) in children aged between six and 12.

Dr Daniel Connor from the University of Connecticut Medical School noted a large number of paediatric patients with the condition experienced anger, defiance and resentfulness, as well as being argumentative with adults.

It can be difficult for caregivers and physicians to find the right medication for children displaying these behaviours, he added.

“These data provide additional support for the clinical efficacy of Intuniv for treating ADHD in this patient population,” commented Dr Connor.

Michael Yasick, senior vice-president of Shire’s ADHD business, explained the results from the trials are a further testament to the business’ commitment to researching the illness and finding new treatment options.

The company filed a new drug application with the Food and Drug Administration for the medication on January 26th 2009.

Once the therapy is available, it will be the first selective alpha-2A receptor agonist permitted to manage the condition.

Last month, Shire released its first quarter financial results and stated it had begun 2009 with a “strong performance”.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.